| breast cancer - triple negative | |||||
| mBC - Triple negative (TNBC) - 1st Line (L1) | mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | mBC - TNBC - L2 - all population | mBC - TNBC - L2 - PDL1 positive | |
| immune chekpoint inhibitors | |||||
| anti-PD-(L)1 | |||||
| atezolizumab based treatment | |||||
| atezolizumab plus nab-paclitaxel | IMpassion-130 ... | IMpassion-130 ... | |||
| atezolizumab plus paclitaxel | IMpassion-131 ... | IMpassion-131 ... | |||
| atezolizumab plus SoC | IMpassion-132 | ||||
| pembrolizumab based treatment | |||||
| pembrolizumab alone | KEYNOTE-119 ... | KEYNOTE-119 ... KEYNOTE-119 ... | |||
| pembrolizumab plus SoC | KEYNOTE-355 ... | KEYNOTE-355 ... KEYNOTE-355 ... | |||
| toripalimab | TORCHLIGHT TORCHLIGHT | ||||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
